Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

NCT05457257 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: olaparib
DRUG: enzalutamide
DRUG: abiraterone acetate
DRUG: Prednisone

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]
[object Object]